Alkermes plc: Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
Alkermes (Nasdaq: ALKS) reported detailed positive Phase 2 Vibrance-2 results for alixorexton in adults with narcolepsy type 2 (n=93). The once-daily drug met dual primary endpoints versus placebo at week 8 on the Maintenance of Wakefulness Test (10 mg, 14 mg p=0.049, 18 mg p=0.047) and Epworth Sleepiness Scale (18 mg p=0.046). Improvements in wakefulness and PROs (fatigue, cognition) were sustained through week 13; alixorexton was generally well tolerated across 10–18 mg with no serious TEAEs.
How this was made
The 30-second read
Why it matters
The disclosed Phase 2 dual-primary success (MWT and ESS at week eight) plus sustained improvements through an open-label extension and a generally favorable safety profile are the key new catalysts. The company also states it has initiated a global Phase 3 program for NT1 and NT2.
Market read
Traders may view this as an incremental probability boost for alixorexton’s Phase 3 success in NT2, given statistically significant improvements on objective wakefulness (MWT) and subjective sleepiness (ESS) with acceptable tolerability.
What to watch
No details on effect size consistency across all doses for both primaries, no comparative efficacy vs existing standards of care, and no update on timelines, funding, or Phase 3 design specifics beyond initiation.
Background
Alkermes is developing alixorexton (formerly ALKS 2680), an oral selective orexin 2 receptor agonist, for narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH). Vibrance-2 is a Phase 2 dose-ranging placebo-controlled study in adults with NT2.
Ticker impact
Alkermes reported Vibrance-2 Phase 2 results where alixorexton met dual primary endpoints (MWT and ESS) at week eight vs placebo in NT2.
Near-term upside bias as traders price higher odds of Phase 3 success; magnitude depends on prior expectations and any upcoming guidance/financing context not provided here.
The article discloses statistically significant improvements at 14 mg and 18 mg for MWT and at 18 mg for ESS, plus no serious TEAEs, which are concrete catalysts for a biotech pipeline name.
Market effects
Strengthens the orexin-2 agonist narrative in hypersomnolence disorders and may lift sentiment for competing CNS sleep/neurology pipeline assets.
Limited direct regional impact; primarily US-listed biotech sentiment.
Global clinical-trial read-through for narcolepsy type 2 and idiopathic hypersomnia programs; could influence international investor appetite for CNS sleep therapeutics.
Counterpoint
Phase 2 success may not translate to Phase 3; the article provides nominal PRO p-values and dose-specific significance, so traders may wait for Phase 3 endpoints and effect size durability.
Key entities
- companyAlkermes plc
Sponsor of the Vibrance-2 Phase 2 study and developer of alixorexton; reported positive NT2 results and initiated Phase 3.
- drug_candidatealixorexton
Investigational oral selective orexin 2 receptor agonist evaluated in Vibrance-2 for narcolepsy type 2.
- clinical_trialVibrance-2 (NCT06555783)
Phase 2 randomized double-blind dose-ranging placebo-controlled study in NT2 (n=93) with primary endpoints MWT and ESS at week eight.
- clinical_programBrilliance Phase 3 program
Global Phase 3 program initiated for once-daily and split dose regimens in NT1 and NT2 (Study 302/303/304 listed).
